Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 10/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723229 | 0.99 | EPHX1 (0.50) | EPHX1MAPTNAMPTPKMALDH1A1 | |
| SCHEMBL7719571 | 0.99 | EPHX1 (0.50) | EPHX1MAPTNAMPTPKMALDH1A1 | |
| SCHEMBL7729158 | 0.99 | EPHX1 (0.50) | EPHX1MAPTNAMPTPKMALDH1A1 | |
| SCHEMBL1677833 | 0.88 | EPHX1 (0.51) | EPHX1MAPTNAMPTPKMALDH1A1 | |
| SCHEMBL1678055 | 0.87 | EPHX1 (0.48) | EPHX1MAPTNAMPTPKMALDH1A1 | |
| SCHEMBL7729401 | 0.87 | HSD17B10 (0.48) | EPHX1MAPTALDH1A1 | |
| SCHEMBL7723097 | 0.86 | HSD17B10 (0.42) | EPHX1MAPTNAMPTALDH1A1 | |
| SCHEMBL1677983 | 0.86 | MAPT (0.47) | EPHX1MAPTNAMPTALDH1A1 | |
| SCHEMBL1677831 | 0.86 | MAPT (0.47) | EPHX1MAPTNAMPTPKMALDH1A1 | |
| SCHEMBL7724934 | 0.85 | EPHX1 (0.41) | EPHX1MAPTNAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1147469-C | Novel urea derivatives bearing nitrogenous aromatic heterocycles | ������ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | EPHX1 1295/4885MAPT 3782/4885NAMPT 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.